ClinicalTrials.Veeva

Menu

The Effects of Non-invasive Brain Stimulation on Treatment Adherence in Schizophrenia

C

Center for Addiction and Mental Health (CAMH)

Status

Enrolling

Conditions

Schizophrenia;Schizoaffective

Treatments

Other: Active TDCS
Other: Sham TDCS

Study type

Interventional

Funder types

Other

Identifiers

NCT04033679
103-2018

Details and patient eligibility

About

This study seeks to explore the effects of transcranial direct current stimulation (tDCS), a non-invasive method of brain stimulation, as an adjunctive treatment to improve antipsychotic medication adherence in patients with schizophrenia (SCZ). The investigators hypothesize that 20 sessions of tDCS will improve medication nonadherence in patients with SCZ.

Full description

The proposed study will investigate the effects of adjunctive tDCS on antipsychotic medication adherence by targeting brain regions implicated in impaired insight, a primary contributor to medication nonadherence in patients with SCZ. Participants will be randomized to receive either active or sham tDCS. tDCS will be administered twice-daily for 10 days (20 sessions) excluding weekends. Brain scans will be performed before and after 10 days of tDCS. Antipsychotic drug adherence will be assessed based primarily on pill-count, and secondarily, plasma level concentrations and clinician-judgement.

Enrollment

106 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Male or female participants of any race or ethnicity
  2. Inpatients or outpatients ≥18 years of age
  3. DSM-V diagnosis of SCZ or schizoaffective disorder
  4. Capable of consenting to participate in the research study
  5. On a stable dose of antipsychotic drug and other concomitant medications for at least 2 months, and unlikely to undergo changes in dose during the study

Exclusion criteria

  1. Unwilling or incapable to consent to the study based on the MacArthur Test of Competence

  2. Unstable medical or any concomitant major medical or neurological illness, including a history of seizures

  3. Acute suicidal or homicidal ideation

  4. Formal thought disorder rating ≥3 on the Positive and Negative Syndrome Scale (PANSS) P2 conceptual disorganization item

  5. DSM-V substance dependence (except caffeine and nicotine) within 1 month of entering the study*

  6. Positive urine drug screen except for cannabis/marijuana at the screening visit

  7. Metal implants or pacemaker precluding an MRI scan or other contraindications to MRI (eg., claustrophobia)

  8. Pregnancy

  9. Score < 32 on the Wide Range Achievement Test-III

    • Substance misuse: In addition to impaired insight, substance misuse is one of the principle contributors to medication nonadherence. To minimize the possibility of its influence, participants with a DSM-V diagnosis of substance dependence within 1 month of entering the study or a positive urine drug test (except for cannabis/marijuana) at the screening visit will be excluded. Substance use and urine drug screens will be assessed at subsequent study visits.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

106 participants in 2 patient groups

Active TDCS
Experimental group
Description:
In the active condition, a constant current of 2 mA intensity will be applied for 20 min to the parietal regions, using P3 as the cathode and P4 as the anode.
Treatment:
Other: Active TDCS
Sham TDCS
Sham Comparator group
Description:
In the sham condition, stimulation will be administered using the same parameters at the site of active treatment, but the current will be turned off after 30 seconds.
Treatment:
Other: Sham TDCS

Trial contacts and locations

1

Loading...

Central trial contact

Philip Gerretsen, MD, PhD; Ariel Graff, MD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems